Supernus Pharmaceuticals, Inc. (SUPN)

Price$44.75

Value ScoreC

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-9.77%

Price vs S&P 500 (4W)-13.15%

VGM Score45.88

Market Capitalization$2.60B

P/E Ratio (Annual)43.28x

All Metrics

P/CF (Annual)54.87x

Book Value / Share (Quarterly)$18.55

P/TBV (Annual)5.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)2.52%

Cash Flow / Share (Quarterly)$1.42

Price vs S&P 500 (YTD)-18.12%

Gross Margin (TTM)89.66%

Net Profit Margin (TTM)-3.74%

EPS (TTM)$-0.51

10-Day Avg Trading Volume0.62M

EPS Excl Extra (TTM)$-0.51

Revenue Growth (5Y)6.68%

EPS (Annual)$-0.68

ROI (Annual)-3.63%

Gross Margin (Annual)89.89%

Net Profit Margin (5Y Avg)4.87%

Cash / Share (Quarterly)$6.62

Revenue Growth QoQ (YoY)38.63%

EPS Growth (5Y)-8.89%

P/E Normalized (Annual)43.28x

ROA (Last FY)-2.65%

Revenue Growth TTM (YoY)16.29%

EBITD / Share (TTM)$0.61

ROE (5Y Avg)3.41%

Operating Margin (TTM)-7.77%

Cash Flow / Share (Annual)$0.80

P/B Ratio2.41x

P/B Ratio (Quarterly)2.76x

Net Income / Employee (Annual)$-49,600

EV / Revenue (TTM)3.11x

Net Interest Coverage (TTM)9.04x

ROA (TTM)-2.02%

EV / EBITDA (TTM)69.01x

EPS Incl Extra (Annual)$-0.68

Current Ratio (Annual)1.90x

Quick Ratio (Quarterly)1.51x

3-Month Avg Trading Volume0.71M

52-Week Price Return38.37%

EV / Free Cash Flow (Annual)52.45x

Revenue / Employee (TTM)$998,500

Tangible BV / Share (Quarterly)$9.08

P/S Ratio (Annual)3.61x

Asset Turnover (Annual)0.49x

52-Week High$59.68

Operating Margin (5Y Avg)4.91%

EPS Excl Extra (Annual)$-0.68

CapEx CAGR (5Y)-17.02%

Tangible BV CAGR (5Y)5.28%

26-Week Price Return-1.84%

Quick Ratio (Annual)1.58x

13-Week Price Return-17.54%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.96x

Enterprise Value$2.41B

Revenue / Share Growth (5Y)5.62%

Asset Turnover (TTM)0.54x

Book Value / Share Growth (5Y)5.59%

Revenue / Employee (Annual)$924,100

Inventory Turnover (Annual)1.06x

Pretax Margin (Annual)-6.82%

Cash / Share (Annual)$5.37

3-Month Return Std Dev32.04%

Gross Margin (5Y Avg)87.93%

Net Income / Employee (TTM)$-37,300

EBITDA CAGR (5Y)-32.18%

EBITDA Interim CAGR (5Y)-2.05%

ROE (Last FY)-3.63%

Net Interest Coverage (Annual)8.96x

EPS Basic Excl Extra (Annual)$-0.68

P/FCF (TTM)18.03x

Receivables Turnover (TTM)4.74x

EV / Free Cash Flow (TTM)29.33x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.51

Receivables Turnover (Annual)4.36x

ROI (TTM)-2.73%

P/S Ratio (TTM)3.34x

Pretax Margin (5Y Avg)6.03%

Revenue / Share (Annual)$12.74

Tangible BV / Share (Annual)$8.57

Forward P/E16.13x

Free OCF CAGR (5Y)-19.37%

Price vs S&P 500 (52W)14.01%

Year-to-Date Return-9.96%

5-Day Price Return-0.02%

EPS Normalized (Annual)$-0.68

ROA (5Y Avg)1.92%

Net Profit Margin (Annual)-5.36%

Month-to-Date Return-3.10%

Cash Flow / Share (TTM)$1.89

EBITD / Share (Annual)$0.48

EPS Growth (3Y)10.38%

Operating Margin (Annual)-8.66%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)31.20x

ROI (5Y Avg)2.56%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.51

P/TBV (Quarterly)5.65x

P/B Ratio (Annual)2.68x

Inventory Turnover (TTM)1.18x

Pretax Margin (TTM)-6.33%

Book Value / Share (Annual)$18.48

Price vs S&P 500 (13W)-25.80%

Net Margin Growth (5Y)-17.27%

Beta0.58x

P/FCF (Annual)56.47x

Revenue / Share (TTM)$13.48

ROE (TTM)-2.73%

52-Week Low$30.83

vGradeC

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.60est. 0.30

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.17

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SUPNSupernus Pharmaceuticals, Inc.	C	D	C	$44.75
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including neurological and psychiatric conditions. Its portfolio of eight marketed products addresses key indications such as epilepsy, migraine, ADHD, Parkinson's disease complications, and dystonia. The company serves underserved patient populations within the neuroscience space.